Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (Weighted Average) (2018 - 2025)

X4 Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $42.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 531.04% year-over-year to $42.3 million; the TTM value through Dec 2025 reached $42.3 million, up 531.04%, while the annual FY2025 figure was $42.3 million, 531.04% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $42.3 million in Q4 2025 per XFOR's latest filing, up from $19.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $170.8 million in Q3 2023 to a low of $3.7 million in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $40.1 million, with a median of $20.0 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 96.08% in 2024, then soared 531.04% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $13.3 million in 2021, then plummeted by 71.87% to $3.7 million in 2022, then skyrocketed by 58.94% to $5.9 million in 2023, then rose by 13.08% to $6.7 million in 2024, then skyrocketed by 531.04% to $42.3 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Shares Outstanding (Weighted Average) are $42.3 million (Q4 2025), $19.2 million (Q3 2025), and $7.4 million (Q2 2025).